For the Inventor, By the Inventor

Enter assignee name

Brooklyn, NY, United States of America

Accutar Biotechnology Inc.

USPTO Granted Patents = 20

% Expired Patents = 25.0

EPO Patents = 5

Trademarks = 2

Forward Citations = 34

Loading Chart...

Loading Chart...

12 inventors (with patents filed for the assignee):

Jie Fan (20 out of 23 patents)

Ke Liu (17 out of 23 patents)

Wei He (13 out of 16 patents)

4. Yimin Qian (10 out of 73 patents)

5. Hui Zhang (3 out of 3 patents)

6. Jie Su (2 out of 5 patents)

7. Ke Liu (2 out of 4 patents)

8. Xiangzhu Wang (1 out of 70 patents)

9. Xiangyan Sun (1 out of 1 patent)

10. Robert Zhiyong Luo (1 out of 15 patents)

11. Sun Xiangyan (1 out of 1 patent)

12. Robert Luo (3 patents)

13. Sun Xiangyan (0 patent)

20 patents: Sort by Forward Citations

1. 12338248 - Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors (2025-06-24),

2. 12331061 - Compounds having BET, estrogen receptor, and androgen receptor degradation activity and uses thereof (2025-06-17),

3. 11642342 - Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer (2023-05-09),

4. 11535606 - Substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof (2022-12-27),

5. 11530222 - Substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders (2022-12-20),

6. 11521712 - Computational method for classifying and predicting ligand docking conformations (2022-12-06),

7. 11420956 - Ureas having Androgen Receptor degradation activity and uses thereof (2022-08-23),

8. 11312702 - Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof (2022-04-26),

9. 11261178 - Chroman derivatives having estrogen receptor degradation activity and uses thereof (2022-03-01),

10. 11220490 - Ureas having androgen receptor degradation activity and uses thereof (2022-01-11),

11. 11117885 - Compounds having estrogen receptor alpha degradation activity and uses thereof (2021-09-14),

12. 10968212 - Compounds having estrogen receptor alpha degradation activity and uses thereof (2021-04-06),

13. 10923214 - Neural network for predicting drug property (2021-02-16),

14. 10836749 - Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof (2020-11-17),

15. 10800770 - Chroman derivatives having estrogen receptor degradation activity and uses thereof (2020-10-13),

Company Overview

Accutar Biotechnology Inc. is a biotechnology company based in Brooklyn, NY, specializing in the development of innovative therapies targeting various diseases, particularly in the oncology and autoimmune sectors. The organization focuses on leveraging advanced drug discovery technologies and precision medicine approaches to create effective treatment options. With a commitment to scientific excellence, Accutar aims to address unmet medical needs through its research initiatives and collaborative efforts within the biopharmaceutical landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

20 Patents

#22 in Brooklyn, NY

#972 in New York

#16,382 in US

#31,233 in the World

Brooklyn, NY, United States of America

Accutar Biotechnology Inc.

Forward Citations = 34

12 inventors:

Jie Fan (20 out of 23 patents)

Ke Liu (17 out of 23 patents)

Wei He (13 out of 16 patents)

4. Yimin Qian (10 out of 73 patents)

5. Hui Zhang (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Accutar Biotechnology Inc.. Retrieved from https://idiyas.com/company/accutar-biotechnology

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…